



To: Transfusion Services Managers
From: Hospital Relations
Date: August 29, 2023
Re: Individualized Donor Assessment

In May of 2023, the FDA published the final guidance document for *Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products*. The guidance provides recommendations for assessing donor eligibility by applying a set of individual risk-based questions that will be asked to every donor, regardless of sexual orientation, sex, or gender.

Carter BloodCare plans to implement the FDA recommendations by November 2023.

The FDA final guidance can be found [here](#) . Please review the attached ABC Blood Bulletin for additional information regarding the guidance.

Please contact hospitalrelations@carterbloodcare.org if you have any questions or concerns.